- $11.45bn
- $16.05bn
- $4.38bn
Catalent Inc reports results for the quarter ended in June 30 - Earnings Summary
Catalent beats revenue estimates ahead of deal close with Novo Nordisk parent
Brief: Catalent Q4 Revenue USD 1,300 Million Vs. IBES Estimate USD 1,224 Million
Catalent Inc expected to post earnings of 47 cents a share - Earnings Preview
Wegovy-maker Novo Nordisk to spend $4.1 bln to boost US manufacturing
Sarepta surges on FDA's expanded use nod for company's Duchenne gene therapy
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Refile: UPDATE 1-Catalent stockholders approve deal with Novo Holdings
Catalent stockholders approve deal with Novo Holdings
Brief: Catalent Stockholders Approve Transaction With Novo Holdings
Brief: Novo Nordisk CEO Expects Data Next Year From Study Of Semaglutide In Alzheimer's Disease
Novo Nordisk owner buys majority stake in Austrian life science tools company
Moves: Lazard hires veteran healthcare dealmaker Colocci as vice chairman
Brief: Catalent Q3 Revenue USD 1,070 Million Vs. IBES Estimate USD 1,120 Million
Brief: Siren Biotechnology And Catalent Enter Partnership For Manufacturing Of AAV Gene Therapies For Cancer
Deals of the day-Mergers and acquisitions
US FTC seeks more information on Novo Nordisk parent-Catalent deal (updated)
FTC seeks more information on Novo Holdings-Catalent deal